Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 2 trial is to study the activity of pembrolizumab in combination
with bevacizumab in patients with untreated brain metastases from melanoma or NSCLC to
determine activity and safety of the drug combination. Furthermore, in patients who undergo
resection of biopsy of a brain metastasis, we will evaluate biomarkers predictive of
treatment benefit, and will also conduct correlative biomarker studies on extra-cerebral
specimens in all patients in whom a systemic biopsy is feasible or in archival tumor tissue
when available.
A total of 53 eligible patients will be enrolled on this trial (40 with melanoma and 13 with
NSCLC). Individual cohorts of the study can be stopped if insufficient activity is observed
in the first stage of that cohort. The study will accrue for approximately 84 months, and
will be open for approximately 12 additional months as patients on study are being followed.